Alector Inc
$ 2.45
2.08%
10 Apr - close price
- Market Cap 264,870,000 USD
- Current Price $ 2.45
- High / Low $ 2.53 / 2.40
- Stock P/E N/A
- Book Value 0.28
- EPS -1.39
- Next Earning Report 2026-05-14
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -1.82 %
- 52 Week High 3.40
- 52 Week Low 0.90
About
Alector, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of neurodegenerative diseases. The company is headquartered in South San Francisco, California.
Analyst Target Price
$2.88
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-03 | 2025-11-06 | 2025-08-07 | 2025-05-06 | 2025-02-25 | 2024-11-05 | 2024-08-07 | 2024-05-08 | 2024-02-27 | 2023-11-07 | 2023-08-03 | 2023-05-04 |
| Reported EPS | -0.34 | -0.34 | -0.3 | -0.41 | -0.02 | -0.43 | -0.4 | -0.38 | -0.49 | -0.53 | 0.02 | -0.55 |
| Estimated EPS | -0.3913 | -0.4 | -0.47 | -0.51 | -0.5443 | -0.53 | -0.5 | -0.51 | -0.77 | -0.66 | -0.82 | -0.76 |
| Surprise | 0.0513 | 0.06 | 0.17 | 0.1 | 0.5243 | 0.1 | 0.1 | 0.13 | 0.28 | 0.13 | 0.84 | 0.21 |
| Surprise Percentage | 13.1101% | 15% | 36.1702% | 19.6078% | 96.3256% | 18.8679% | 20% | 25.4902% | 36.3636% | 19.697% | 102.439% | 27.6316% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-14 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.34 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ALEC
2026-04-05 20:40:20
Alector, Inc. (ALEC) is a clinical-stage biotechnology company developing therapies for neurodegenerative diseases. The company is currently unprofitable and its shares have experienced significant volatility. Despite recent analyst upgrades and some positive news regarding its pipeline, insider selling and a previous clinical trial failure of Latozinemab suggest ongoing challenges, with market analysts holding a mixed outlook on its valuation.
2026-04-03 07:40:39
This page provides financial data, specifically working capital per share, for Alector, Inc. (0Z2) on the Gettex exchange. It appears to be a financial data portal displaying key metrics for interested investors. The data listed for "Period Value Change Change %" is currently empty.
2026-04-01 17:39:29
Alector (ALEC) shares surged 19.8% in intraday trading on April 1, 2026, reaching $2.575, driven by short-term technical momentum and speculative options positioning. High volume in April 17 call options at the $2.5 strike suggests traders are anticipating a continued rally. While technical indicators show bullish signs, historical backtesting of similar surges yielded mixed long-term results, leading investors to question if this is a true breakout or a temporary spike.
2026-04-01 16:39:29
This article identifies several healthcare stocks that experienced significant intraday movement on Wednesday, listing both gainers and losers. Cyclerion Therapeutics and Axe Compute saw substantial increases, while ORIC Pharmaceuticals and Bristol-Myers Squibb Company Celegne Contingent Value Rights were among those that declined. The movements are attributed to various factors including recent earnings reports.
2026-03-31 12:10:16
This article analyzes Alector (ALEC) stock's recent technical performance, highlighting a "golden cross" event where its 50-day moving average surpassed its 200-day moving average. This technical indicator suggests a potentially strong short-to-medium-term upward trend for the stock, making it an attractive prospect for investors.
2026-03-30 06:10:51
This article reports a significant increase in the price target for Alector (ALEC) stock. The target has been raised by 37.14% to $2.94. This adjustment could indicate a more optimistic outlook on the company's future performance by analysts.
